ICON plc vs Novotech

Auto-generated comparison by BioBM Editorial AI. This page highlights available profile evidence side by side and avoids drawing conclusions from missing fields.

Markdown mirror: /api/markdown/compare/iconplc/novotech-cro

Category	ICON plc	Novotech
Listed site	cro	cro
Summary	ICON is a world-leading clinical research organization providing outsourced services across the full clinical trial lifecycle, from early phase through commercialization, to pharmaceutical, biotechnology, and medical device companies.	Global full-service CRO specializing in early-phase and oncology trials across 50+ countries, with expertise in cardiovascular, cell and gene therapy, and radiopharmaceutical development.
Services	Phase I Clinical Trials Phase II Clinical Trials Phase III Clinical Trials Phase IV / Post-Marketing Clinical Operations Clinical Trial Services Clinical Imaging Core Lab Central Laboratory Services Data Management & eClinical Biostatistics & Statistical Programming Medical Writing Pharmacovigilance & Drug Safety Regulatory Affairs US FDA Regulatory Strategy EU EMA Regulatory Strategy Flow Cytometry Services Bioanalysis Translational Research Biomarker Assays Immunogenicity Assays (ADA / NAb) Ligand-Binding Bioanalysis (Large Molecule) LC-MS Bioanalysis (Small Molecule) Cardiovascular & Metabolic Specialty Services CNS Specialty Services Oncology Specialty Services Immunology & Inflammation Services Companion Diagnostics Development Japan PMDA Regulatory Strategy China NMPA Regulatory Strategy	Phase I Clinical Trials Phase II Clinical Trials Phase III Clinical Trials Phase IV / Post-Marketing Clinical Operations Oncology Specialty Services Cardiovascular & Metabolic Specialty Services Immunology & Inflammation Services Regulatory Affairs US FDA Regulatory Strategy EU EMA Regulatory Strategy China NMPA Regulatory Strategy Japan PMDA Regulatory Strategy Medical Writing Pharmacovigilance & Drug Safety Biostatistics & Statistical Programming Data Management & eClinical Central Laboratory Services Bioanalysis
Modalities	Small Molecule Biologics (Monoclonal Antibodies) Biologics (Other) Cell Therapy Gene Therapy Vaccine	Biologics (Monoclonal Antibodies) Biologics (Other) Cell Therapy Gene Therapy Radiopharmaceutical
Indications	Cardiovascular Neurology Immunology Oncology Infectious Disease Metabolic Rare Disease Women's Health Ophthalmology	Oncology Immunology Cardiovascular
Locations	Headquarters, Dublin, Ireland Belgium, Belgium, Belgium Bulgaria, Bulgaria, Bulgaria Germany, Germany, Germany Hungary, Hungary, Hungary Italy, Italy, Italy Netherlands, Netherlands, Netherlands Poland, Poland, Poland Romania, Romania, Romania Slovakia, Slovakia, Slovakia South Africa, South Africa, South Africa Spain, Spain, Spain Türkiye, Türkiye, Türkiye United Kingdom, United Kingdom, United Kingdom Australia, Australia, Australia China, China, China India, India, India Japan, Japan, Japan Korea, Korea, Korea Malaysia, Malaysia, Malaysia Taiwan, Taiwan, Taiwan Argentina, Argentina, Argentina Brazil, Brazil, Brazil Chile, Chile, Chile Colombia, Colombia, Colombia Mexico, Mexico, Mexico Belgium, Belgium, Belgium Bulgaria, Bulgaria, Bulgaria Germany, Germany, Germany Hungary, Hungary, Hungary Italy, Italy, Italy Netherlands, Netherlands, Netherlands Poland, Poland, Poland Romania, Romania, Romania Slovakia, Slovakia, Slovakia South Africa, South Africa, South Africa Spain, Spain, Spain Türkiye, Türkiye, Türkiye United Kingdom, United Kingdom, United Kingdom Australia, Australia, Australia China, China, China India, India, India Japan, Japan, Japan Korea, Korea, Korea Malaysia, Malaysia, Malaysia Taiwan, Taiwan, Taiwan Argentina, Argentina, Argentina Brazil, Brazil, Brazil Chile, Chile, Chile Colombia, Colombia, Colombia Mexico, Mexico, Mexico United States, United States, United States	Headquarters, Sydney, New South Wales, Australia Regional Office, Singapore, Singapore
Certifications	Data not yet provided.	Data not yet provided.
Reviews	Review summary appears after site-level review signal gate opens.	Review summary appears after site-level review signal gate opens.